News Scholar Rock gets first drug approval as FDA okays Isembyld Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.
News Manufacturing issues block FDA nod for Scholar Rock SMA drug Unresolved issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's SMA drug apitegromab.
News Scholar Rock preps filings after SMA antibody clears trial Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory fi
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.